Clinical Impact of ALK Inhibitor Data: Efficacy, Brain Metastases, and CNS Management Strategies
Panelists discuss how recent data influence treatment choices for ALK-positive NSCLC patients, highlighting specific patient factors that guide decisions and potential concerns regarding the use of lorlatinib as first-line therapy.
Video Player is loading.
- Dr Gadgeel: How do these data impact your treatment choice for your patients?
- What specific patient factors would influence your decision between treatment options? What concerns might prevent you from choosing lorlatinib as a first-line treatment?
Related Content:
